AiCuris
Germany - WuppertalBiotechnology
Focus: AiCuris is a German biotech company specializing in anti-infective therapeutics, focused on viral infections including HSV, CMV, and BK virus. Recently acquired by Japan's Asahi Kasei in April 2026, expanding its antiviral asset portfolio.
Profile data last refreshed 9m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
2
Should You Work at AiCuris?
AI assessmentA niche anti-infectives player with meaningful Phase 3 momentum and new parent-company backing, best suited for specialists willing to bet on pipeline catalysts over near-term commercial scale.
Why Work Here
- Lead a Phase 3 HSV program (pritelivir) with 4 active trials, offering visibility into near-term regulatory catalysts and commercial potential.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)
Urinary Tract InfectionsClinical Trials (1)
NCT02641015Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)
N/AHelp build intelligence for AiCuris
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.